Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11010315 | 0.88 | LDHA (0.66) | LDHAHTTALDH1A1PKMALOX15 | |
| SCHEMBL28672180 | 0.86 | LDHA (0.52) | LDHAALDH1A1PKMALOX15LMNA | |
| SCHEMBL26288572 | 0.86 | ALDH1A1 (0.45) | LDHAALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL5986172 | 0.86 | LDHA (0.68) | LDHAHTTKDM4EMITFALDH1A1 | |
| SCHEMBL2043106 | 0.85 | MMP8 (0.43) | LDHAALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL31361313 | 0.84 | LDHA (0.50) | LDHAKDM4EALDH1A1PKMALOX15 | |
| SCHEMBL3773692 | 0.84 | LDHA (0.50) | LDHAHTTALDH1A1PKMALOX15 | |
| SCHEMBL28670825 | 0.84 | LDHA (0.50) | LDHAKDM4EALDH1A1PKMALOX15 | |
| SCHEMBL15668966 | 0.84 | HTT (0.51) | LDHAHTTKDM4EMITFALDH1A1 | |
| SCHEMBL2426652 | 0.84 | LDHA (0.47) | LDHAPKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| EP-2163555-A1 | New pyrazole derivatives and diabetic medicine containing them | Ajinomoto Co., Inc. (JP) | 2010-03-17 | — | — | EP | disclosed |
| EP-2163555-A1 | New pyrazole derivatives and diabetic medicine containing them | Ajinomoto Co., Inc. (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-05-03 | — | — | US | disclosed |
| US-7015201-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20060058244-A1 | New pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | AJINOMOTO CO. INC (JP) | 2005-06-30 | — | — | US | disclosed |
| US-20050043249-A1 | New pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1500403-A1 | PREVENTIVE/REMEDY FOR DIABETES | Ajinomoto Co., Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6815428-B2 | AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1338603-A1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | SLC5A2, SLC5A1, DPP4 | LDHA 938/4885HTT 4852/4885KDM4E 3288/4885 |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | LDHA 1502/4885HTT 4867/4885KDM4E 3289/4885 |
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | LDHA 2821/4885HTT 2866/4885KDM4E 4506/4885 |
| US-20060058244-A1 | New pyrazole derivatives and diabetic medicine containing them | DPP4, SLC5A2, SLC5A1 | LDHA 1502/4885HTT 4867/4885KDM4E 3289/4885 |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | LDHA 1502/4885HTT 4867/4885KDM4E 3289/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | LDHA 2821/4885HTT 2866/4885KDM4E 4506/4885 |
| US-20050043249-A1 | New pyrazole derivatives and diabetic medicine containing them | DPP4, SLC5A2, SLC5A1 | LDHA 1502/4885HTT 4867/4885KDM4E 3289/4885 |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | SLC5A2, SLC5A1, GPR119 | LDHA 337/4885HTT 2169/4885KDM4E 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.